RxDoctor Payments Data

Joseph Kiss

Pittsburgh, PANPI 1871567065

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Sanofi at 58.1% of the total. Reporting peaked in 2020 at $21,398 and has fallen 66.4% since, to $7,199 in 2024.

$74,665in general payments, 2019–2025

Across 88 payments — averaging $848.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$43K
  • Haemonetics Corporation$14K
  • Sanofi-aventis U.S. LLC$9K
  • Grifols Shared Services North America, Inc.$5K
  • Kaneka Medical America LLC$3K
  • AstraZeneca$190
  • plus $158 from 4 others
$179,783in research payments, 2019–2025

Across 15 payments — averaging $11,986 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$82K
  • Sanofi$59K
  • Bioverativ Therapeutics Inc.$28K
  • Ablynx NV$11K

What the payments were for

  • Consulting fees$42,30957%
  • Speaking & faculty fees$23,57832%
  • Travel & lodging$6,7049%
  • Food & beverage$2,0743%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →